SCHEMBL5401210

SCHEMBL5401210

Cc1c(OC2CCCC(N(c3ccccc3)c3ccccc3)C2)ccc2[nH]ncc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.34
TYRO3 Q06418 1/20 0.34
MERTK Q12866 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
PDK1 Q15118 1/20 0.32
TRPV1 Q8NER1 2/20 0.32
ROCK2 O75116 2/20 0.32
ROCK1 Q13464 2/20 0.32
ARHGDIA P52565 1/20 0.32
CCNB2 O95067 1/20 0.32
CCNE2 O96020 1/20 0.32
CDK1 P06493 1/20 0.32
CCNB1 P14635 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
CCNB3 Q8WWL7 1/20 0.32
CSF1R P07333 1/20 0.31
METAP2 P50579 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401202 1.00 AXL (0.34) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5401207 1.00 AXL (0.34) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5412792 0.90 AXL (0.34) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5412795 0.90 AXL (0.34) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5412791 0.90 AXL (0.34) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5401742 0.85 AXL (0.37) AXLTYRO3MERTKS1PR1
SCHEMBL5401746 0.85 AXL (0.37) AXLTYRO3MERTKS1PR1
SCHEMBL5412290 0.84 SLC6A4 (0.38) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5412301 0.84 SLC6A4 (0.38) AXLTYRO3MERTKSLC6A2SLC6A4
SCHEMBL5412296 0.84 SLC6A4 (0.38) AXLTYRO3MERTKSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA AXL 1805/4885TYRO3 961/4885MERTK 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.